Top 5 Surgical Takeaways From NCCN Breast Cancer Congress for Invasive Breast Cancer
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers: The FDA has imposed a partial clinical hold on the Lorigerlimab trial due to reported severe safety events. Implications of this are currently under analysis.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: Great strides are being made in managing toxicities during melanoma treatment using immune-checkpoint inhibitors. Further study is ongoing.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: SRN-101 has gained FDA Fast Track Designation for addressing recurrent high-grade glioma, signifying a vital step forward.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: Preliminary research indicates that KTX-1001, a new molecule, exhibits great potential in treating pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: In-depth analysis contrasting quality of life outcomes with proton therapy and photon therapy in oropharyngeal cancer treatment is shedding new light on preferred practices.
